Provided by Tiger Trade Technology Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.73
+0.05503.29%
Volume:634.74K
Turnover:1.09M
Market Cap:146.92M
PE:-2.18
High:1.74
Open:1.69
Low:1.66
Close:1.67
52wk High:3.06
52wk Low:0.6254
Shares:85.17M
Float Shares:78.81M
Volume Ratio:1.05
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7900
EPS(LYR):-0.6674
ROE:-260.65%
ROA:-41.97%
PB:7.17
PE(LYR):-2.58

Loading ...

Mar 21, 2024

Major Issues Report

Form 8-K - Current report
Mar 21, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 04, 2024

Major Issues Report

Form 8-K - Current report
Feb 26, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 30, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Dec 26, 2023

Major Issues Report

Form 8-K - Current report
Nov 13, 2023

Major Issues Report

Form 8-K - Current report
Nov 13, 2023

Major Issues Report

Form 8-K - Current report
Nov 13, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2023

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
Nov 07, 2023

Major Issues Report

Form 8-K - Current report
Oct 24, 2023

Major Issues Report

Form 8-K - Current report
Aug 10, 2023

Major Issues Report

Form 8-K - Current report
Aug 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 09, 2023

Major Issues Report

Form 8-K - Current report
May 31, 2023

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
May 24, 2023

Correspondence

Form CORRESP - Correspondence
May 11, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]